HIGHLIGHTS
SUMMARY
Unger and colleagues estimated that fewer than 1 in 20 patients in the the authors participate in clinical trials, and those participants are typically medically fit, younger, and healthier than the general population. The historical paradigm of clinical trials adding novel agents to improve survival is shifting toward a more individualized approach to treatment based on patients` risk profiles, with the emergence of clinical trials testing less intense treatment approaches. In the absence of data for underrepresented patient groups from trials, physicians must decide whether to de-implement and how to discuss applicability of . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.